Floatz logo

Campath-1H

Myeloma

David Rizzieri, MDmonoclonal_antibodyPhase 2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

17 Active assets in the Myeloma cohort.

Asset / SponsorPhaseRating
SULFAMETHOXAZOLE
Monash University
Phase 3BB
Trimethoprim
Monash University
Phase 3BB
HUMAN IMMUNOGLOBULINS
Monash University
Phase 2/3BB
Lipitor
Fred Hutchinson Cancer Center
Phase 2BB
Campath
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2B

View all 43 →

Same molecule, other indications

Campath-1H is also rated in:

MyelodysplasiaDormant
CCC
Indicative ·
55 / 100
View asset →
myelodysplastic syndromeDormant
CCC
Indicative ·
49 / 100
View asset →
lymphomaDormant
CCC
Indicative ·
49 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →